Thousands of abstracts were submitted for the recent Asco meeting in Chicago and 40,000 oncology professionals gathered to delve into cutting-edge research, practice-changing science, and the ever-evolving models for quality care. 

The Evaluate Vantage team was there to report back on the key highlights and keep you abreast of the big announcements, including the results of the Tropics-02 trial and potential shifts that may redefine how we think about breast cancer. They also look at the likely stock market implications of what was said (and not said) during the meeting.  

In this ebook, we bring together all the big news – and our team’s analysis – of ASCO 2022, and ponder questions.



Where were the rich pickings for biotech investors?
Is there still space for new Car-T therapies in multiple myeloma? Just how bad were the results of the Skyscraper-02 trial – and what does it mean for investors?
What’s next in Her2-low breast cancer?